BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8980393)

  • 21. Synthesis, antiproliferative activity and DNA binding study of mixed ammine/cyclohexylamine platinum(II) complexes with 1-(substituted benzyl) azetidine-3, 3-dicarboxylates.
    Sun Y; Gou S; Yin R; Jiang P
    Eur J Med Chem; 2011 Oct; 46(10):5146-53. PubMed ID: 21875765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
    Sharp SY; Rogers PM; Kelland LR
    Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preclinical antitumor activity of orally administered platinum (IV) complexes.
    Rose WC; Crosswell AR; Schurig JE; Casazza AM
    Cancer Chemother Pharmacol; 1993; 32(3):197-203. PubMed ID: 8500224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism, protein binding and in vivo activity of the oral platinum drug JM216 and its biotransformation products.
    Raynaud FI; Boxall FE; Goddard P; Barnard CF; Murrer BA; Kelland LR
    Anticancer Res; 1996; 16(4A):1857-62. PubMed ID: 8712713
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-activity relationship of new trans-platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death.
    González-Vadillo AM; Alvarez-Valdés A; Moneo V; Blanco F; Díaz RG; Carnero A; Navarro-Ranninger C
    J Inorg Biochem; 2007 Apr; 101(4):551-8. PubMed ID: 17257684
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents.
    McKeage MJ; Morgan SE; Boxall FE; Murrer BA; Hard GC; Harrap KR
    Br J Cancer; 1993 May; 67(5):996-1000. PubMed ID: 8494733
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
    Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of cellular accumulation and cytotoxicity of cisplatin with that of tetraplatin and amminedibutyratodichloro(cyclohexylamine)platinum(IV) (JM221) in human ovarian carcinoma cell lines.
    Mistry P; Kelland LR; Loh SY; Abel G; Murrer BA; Harrap KR
    Cancer Res; 1992 Nov; 52(22):6188-93. PubMed ID: 1423261
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin.
    Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
    J Cancer Res Clin Oncol; 1994; 120(10):571-7. PubMed ID: 7929527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ammine/amine platinum(IV) dicarboxylates: a novel class of platinum complex exhibiting selective cytotoxicity to intrinsically cisplatin-resistant human ovarian carcinoma cell lines.
    Kelland LR; Murrer BA; Abel G; Giandomenico CM; Mistry P; Harrap KR
    Cancer Res; 1992 Feb; 52(4):822-8. PubMed ID: 1737343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent and non-specific inhibition of cytochrome P450 by JM216, a new oral platinum agent.
    Ando Y; Shimizu T; Nakamura K; Mushiroda T; Nakagawa T; Kodama T; Kamataki T
    Br J Cancer; 1998 Nov; 78(9):1170-4. PubMed ID: 9820175
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors.
    Yoshida M; Khokhar AR; Zhang YP; Thai G; Siddik ZH
    Cancer Chemother Pharmacol; 1994; 35(1):38-44. PubMed ID: 7987975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulatory effect of axial and equatorial ligands on antitumor activities of trans-1R,2R-diaminocyclohexane platinum(IV) complexes.
    Siddik ZH; al-Baker S; Thai G; Khokhar AR
    Anticancer Drug Des; 1994 Apr; 9(2):139-51. PubMed ID: 8166929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and antitumor activity of ammine/amine platinum(II) and (IV) complexes.
    Khokhar AR; Deng Y; al-Baker S; Yoshida M; Siddik ZH
    J Inorg Biochem; 1993 Aug; 51(3):677-87. PubMed ID: 8409984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of apoptosis in cell killing by cisplatin: a flow cytometric study.
    Ormerod MG; Orr RM; Peacock JH
    Br J Cancer; 1994 Jan; 69(1):93-100. PubMed ID: 8286217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of two Pt(IV) complexes on viability, apoptosis and cell cycle of B16 mouse melanoma tumors.
    Kaznica A; Drewa T; Lakomska I; Ryta-Stamirowska P; Debski R; Styczynski J; Drewa G; Szlyk E
    Exp Oncol; 2009 Mar; 31(1):33-6. PubMed ID: 19300414
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Platinum coordination complexes which circumvent cisplatin resistance.
    Harrap KR; Kelland LR; Jones M; Goddard PM; Orr RM; Morgan SE; Murrer BA; Abrams MJ; Giandomenico CM; Cobbleigh T
    Adv Enzyme Regul; 1991; 31():31-43. PubMed ID: 1877393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Schedule dependency of orally administered bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) in vivo.
    McKeage MJ; Kelland LR; Boxall FE; Valenti MR; Jones M; Goddard PM; Gwynne J; Harrap KR
    Cancer Res; 1994 Aug; 54(15):4118-22. PubMed ID: 8033145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound.
    Bates PI; Sharma HL; Murrer BA; McAuliffe CA
    Cancer Chemother Pharmacol; 1996; 39(1-2):170-5. PubMed ID: 8995517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.